Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra Navarra, Renato Guzmán, A Gallacher et al. · The Lancet · 2011 · 2K citations

Medicine, Immunology, Pharmacology +11

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie, Michelle Petri, Omid Zamani et al. · Arthritis & Rheumatism · 2011 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations

Fabienne Mackay, Stephen A. Woodcock, Pornsri Lawton et al. · The Journal of Experimental Medicine · 1999 · 1.5K citations · Full text

Life Sciences, Immunology, Pathology +17

BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

Pascal Schneider, Fabienne Mackay, Véronique Steiner et al. · The Journal of Experimental Medicine · 1999 · 1.3K citations · Full text

Life Sciences, Immunology, Molecular Biology +17

EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome

Raphaèle Séror, Philippe Ravaud, Simon Bowman et al. · Annals of the Rheumatic Diseases · 2009 · 945 citations · Full text

Life Sciences, Immunology, Internal Medicine +16